{"id":"NCT03907241","sponsor":"Octapharma","briefTitle":"CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL","officialTitle":"Title for SCGAM-03: CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES WHO HAVE COMPLETED THE SCGAM-01 TRIAL Title for SCGAM-03 in Canada: CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-01","primaryCompletion":"2019-09-05","completion":"2019-09-05","firstPosted":"2019-04-08","resultsPosted":"2020-09-22","lastUpdate":"2020-10-27"},"enrollment":27,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency"],"interventions":[{"type":"DRUG","name":"Octanorm 16.5%","otherNames":[]}],"arms":[{"label":"Octanorm 16.5%","type":"EXPERIMENTAL"}],"summary":"Summary for SCGAM-03: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (Octanorm) in patients with primary immunodeficiency diseases who have completed the SCGAM-01 trial.\n\nSummary for SCGAM-03 in Canada: Clinical phase III study to monitor the safety, tolerability and efficacy of subcutaneous human immunoglobulin (octanorm) in patients with primary immunodeficiency diseases, including (but not limited to) those who have completed the SCGAM-01 trial","primaryOutcome":{"measure":"Occurrence of All Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From study start to end, up to 3.5 years","effectByArm":[{"arm":"Age >=2 to <6","deltaMin":8,"sd":null},{"arm":"Age >=6 to <12","deltaMin":19,"sd":null},{"arm":"Age >=12 to <17","deltaMin":22,"sd":null},{"arm":"Age >=17 to <=75","deltaMin":155,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":7,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["Sinusitis","Bronchitis","Influenza","Nasopharyngitis","Headache"]}}